ArticleAmerican journal of cancer research2017
Eight-plex iTRAQ labeling and quantitative proteomic analysis for human bladder cancer.
Article in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- A scaffold attachment factor PHM-2 regulates synaptic transmission through SLO-2 potassium channel in C. elegans.PLoS genetics · 2026Article
- A scaffold attachment factor PHM-2 regulates synaptic transmission through SLO-2 potassium channel inbioRxiv : the preprint server for biology · 2025Article
- RANBP1 promotes colorectal cancer progression by regulating pre-miRNA nuclear export via a positive feedback loop with YAP.Oncogene · 2022Article
- Identification of Potential Biomarkers for Progression and Prognosis of Bladder Cancer by Comprehensive Bioinformatics Analysis.Journal of oncology · 2022Article
- A Novel Quantification System Combining iTRAQ Technology and Multi-Omics Assessment to Predict Prognosis and Immunotherapy Efficacy in Colon Cancer.Frontiers in bioengineering and biotechnology · 2022Article
- High expression of Ran binding protein 1 predicts poor outcomes in hepatocellular carcinoma patients: a Cancer Genome Atlas database analysis.Journal of gastrointestinal oncology · 2021Article
- Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?Translational andrology and urology · 2021Review
- Quantitative proteomics identifies a plasma multi-protein model for detection of hepatocellular carcinoma.Scientific reports · 2020Article
- WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness.British journal of cancer · 2020Article
- Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics.Journal of food and drug analysis · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is one of the most prevalent cancers worldwide, and increasing research has focused on new technologies for early detection of bladder cancer. For example, proteomic techniques for biomarker discovery have been implemented for the detection and analysis of protein changes in the tissues, blood, and urine from bladder cancer patients. In this present study, we evaluated the effectiveness of the eight-plex iTRAQ labeling and quantitative proteomic approaches for differentially analyzing proteins found in normal and bladder cancer tissues from individual patients. This study obtained 1627 identified and quantified proteins, and detected significant changes of expression in 35 proteins. In addition, both mass spectrometry and Western Blot results indicated that scaffold attachment factor B (SafB) and GTPase RAN binding protein 1 (RanBP1) were up-regulated in low-grade bladder cancer tissues. Overall, this study suggests that these two proteins are potential candidates as predictive and diagnostic biomarkers and that they may be potentially used as the therapeutic targets for drug discovery.
Indexed as
Identifiers
28469965PMC5411800W2941689170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.